Does restaging MRI radiomics analysis improve pathological complete response prediction in rectal cancer patients? A prognostic model development
- PMID: 34725772
- DOI: 10.1007/s11547-021-01421-0
Does restaging MRI radiomics analysis improve pathological complete response prediction in rectal cancer patients? A prognostic model development
Abstract
Purpose: Our study investigated the contribution that the application of radiomics analysis on post-treatment magnetic resonance imaging can add to the assessments performed by an experienced disease-specific multidisciplinary tumor board (MTB) for the prediction of pathological complete response (pCR) after neoadjuvant chemoradiotherapy (nCRT) in locally advanced rectal cancer (LARC).
Materials and methods: This analysis included consecutively retrospective LARC patients who obtained a complete or near-complete response after nCRT and/or a pCR after surgery between January 2010 and September 2019. A three-step radiomics features selection was performed and three models were generated: a radiomics model (rRM), a multidisciplinary tumor board model (yMTB) and a combined model (CM). The predictive performance of models was quantified using the receiver operating characteristic (ROC) curve, evaluating the area under curve (AUC).
Results: The analysis involved 144 LARC patients; a total of 232 radiomics features were extracted from the MR images acquired post-nCRT. The yMTB, rRM and CM predicted pCR with an AUC of 0.82, 0.73 and 0.84, respectively. ROC comparison was not significant (p = 0.6) between yMTB and CM.
Conclusion: Radiomics analysis showed good performance in identifying complete responders, which increased when combined with standard clinical evaluation; this increase was not statistically significant but did improve the prediction of clinical response.
Keywords: Magnetic resonance imaging; Multidisciplinary tumor board; Neoadjuvant chemoradiation; Radiomics; Rectal cancer; Response prediction.
© 2021. Italian Society of Medical Radiology.
References
-
- Benson AB, Al-Hawary MM, Arain MA, Chen Y-J, Ciombor KK, Cohen S, Deming D, Garrido-Laguna I, Grem JL, Buffett P, Hoffe S, Hubbard J, Hunt S, Kirilcuk N, Krishnamurthi S, Messersmith WA, Meyerhardt J, Brigham D-F, Miller CD, Nurkin S, Overman MJ, Parikh A, Patel H, Pedersen K, Saltz L, Schneider C, Shibata D, Skibber JM, Sofocleous CT, Stoffel EM, Stotsky-Himelfarb E, Willett CG, Gurski L, Johnson-Chilla A (2020) NCCN Guidelines Insights: Rectal Cancer, Version 6.2020. J Natl Compr Canc Netw 18(7):806–815. https://doi.org/10.6004/jnccn.2020.0032 - DOI - PubMed
-
- Li Y, Wang J, Ma X, Tan L, Yan Y, Xue C, Hui B, Liu R, Ma H (2016) A review of neoadjuvant chemoradiotherapy for locally advanced rectal cancer. Int J Biol Sci. https://doi.org/10.7150/ijbs.15438 - DOI - PubMed - PMC
-
- Monson JRT, Weiser MR, Buie WD, Chang GJ, Rafferty JF (2013) Practice parameters for the management of rectal cancer (revised). Dis Colon Rectum 56:535–550. https://doi.org/10.1097/DCR.0b013e31828cb66c - DOI - PubMed
-
- Yuval JB, Thompson HM, Garcia-Aguilar J (2020) Organ preservation in rectal cancer. J Gastrointest Surg. https://doi.org/10.1007/s11605-020-04583-w - DOI - PubMed - PMC
-
- Sanghera P, Wong DWY, McConkey CC, Geh JI, Hartley A (2008) Chemoradiotherapy for rectal cancer: an updated analysis of factors affecting pathological response. Clin Oncol 20:176–183. https://doi.org/10.1016/j.clon.2007.11.013 - DOI
MeSH terms
LinkOut - more resources
Full Text Sources
Medical
